Unsafe use of intravenous haloperidol: Evaluation of recommendation- concordant care in hospitalized elderly adults

Journal of the American Geriatrics Society

Volumn 61, Issue 1, 2013, Pages 160-161

  Cheung, Dora ^a   Wolfe, Brian ^b   Wald, Heidi ^b   Cumbler, Ethan ^b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

AGED; AGED HOSPITAL PATIENT; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY; DELIRIUM; ELECTROCARDIOGRAM; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; QT PROLONGATION; RETROSPECTIVE STUDY; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; COLORADO; DEATH, SUDDEN, CARDIAC; DELIRIUM; ELECTROCARDIOGRAPHY; FEMALE; HALOPERIDOL; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; INPATIENTS; MALE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TORSADES DE POINTES;

EID: 84872222369     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12049     Document Type: Letter

References (10)

1. Inouye SK,. Delirium in older persons. N Engl J Med 2006; 354: 1156-1165.
2. Saxena S, Lawley D,. Delirium in the elderly: A clinical review. Postgrad Med J 2009; 85: 405-413.
3. Fong TG, Tulebae SR, Inouye SK,. Delirium in elderly adults: Diagnosis, prevention, and treatment. Nat Rev Neurol 2009; 5: 210-220.
4. Witlox J, Eurelings LSM, de Jonghe JFM, et al. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia. JAMA 2010; 304: 443-451.
5. Lonergan E, Britton AM, Luxenberg J,. Antipsychotics for delirium. Cochrane Database Syst Rev 2007; 2: CD005594.
6. Information for Healthcare Professionals: Haloperidol [on-line]. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm Accessed May 2012.
7. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-2127.
8. Crouch MA, Limon L, Cassano AT,. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003; 23: 881-908.
9. Li EC, Esterly JS, Pohl S, et al. Drug-induced QT-interval prolongation: Considerations for the clinicians. Pharmacotherapy 2010; 30: 684-701.
10. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsades de Pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-1060.